Effects of early inhaled beclomethasone therapy on tracheal aspirate inflammatory mediators IL-8 and IL-1ra in ventilated preterm infants at risk forbronchopulmonary dysplasia
Gk. Gupta et al., Effects of early inhaled beclomethasone therapy on tracheal aspirate inflammatory mediators IL-8 and IL-1ra in ventilated preterm infants at risk forbronchopulmonary dysplasia, PEDIAT PULM, 30(4), 2000, pp. 275-281
We tested the hypothesis that inhaled beclomethasone therapy for prevention
of bronchopulmonary dysplasia (BPD) reduces pulmonary inflammation. As par
t of a randomized, placebo-controlled trial, interleukin-8 (IL-8) and inter
leukin-l receptor antagonist (IL-1ra) concentrations in tracheal aspirates
were measured as markers of pulmonary inflammation. On study days 1 (baseli
ne), 8, 15, and day 28 of age, samples were obtained from enrolled infants
(birth weights <1,251 g, gestational age <33 week, 3 to 14 days of age) who
remained ventilated and had not received systemic glucocorticoid therapy.
Cytokine levels (pg/mu g of free secretory component of immunoglobulin A) w
ere compared between groups. We determined whether baseline cytokine levels
modified treatment effect regarding subsequent need for systemic glucocort
icoid therapy or occurrence of BPD (age 28 days).
Tracheal aspirates were obtained from 161 infants (77 receiving beclomethas
one, 84 receiving placebo). Median IL-8 levels were lower in beclomethasone
versus placebo infants on study days 8 (82.9 vs. 209.2, P < 0.01) and 15 (
37.4 vs. 77.4, P < 0.03) after controlling for antenatal glucocorticoid the
rapy and maternal race. Median IL-1ra levels were lower in beclomethasone v
ersus placebo infants only on study day 8 (86.5 vs. 153.3, P< 0.01). Fewer
beclomethasone infants with baseline IL-8 levels in the interquartile range
required systemic glucocorticoid therapy (beclomethasone 30.6% vs. placebo
65.8%, P < 0.01) or developed BPD (beclomethasone 42.4% vs, placebo 69.4%,
P < 0.03).
We conclude that early-inhaled beclomethasone therapy was associated with a
reduction in pulmonary inflammation after 1 week of therapy. Beclomethason
e-treated infants with moderately elevated baseline IL-8 levels received le
ss subsequent systemic glucocorticoid therapy and had a lower incidence of
BPD than nontreated infants. Pediatr Pulmonol. 2000; 30:275-281, (C) 2000 W
iley-Liss, Inc.